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Abstract 
 The extra-cellular matrix protein Fibronectin (FN) plays an important role in cell 
contractility, differentiation, growth, adhesion, and migration. The 12th -14th Type III 
repeats of FN (FNIII 12-14), also referred to as the Heparin II domain, comprise a highly 
promiscuous growth factor (GF) binding region. This binding domain aids in cellular 
signaling initiated from the ECM. Additionally, FN has the ability to assemble into fibrils 
under certain conditions, mostly observed during cell contractile processes such as 
those that initiate due to upregulation of Transforming Growth Factor Beta 1 (TGF-β1) 
[1], [2]. Previous work from our lab has shown that self-assembly of FN into insoluble 
fibrils is crucial for Epithelial-Mesenchymal Transition (EMT) [3]. The transition from 
epithelial to mesenchymal cell type has been implicated as an early event in tumor 
formation and breast cancer. We were previously able to find that upregulation of FN 
fibrils drive EMT through contractility due to the increase of the GF latent TGF-β 
complex concentration at the cell membrane [3]. 
 The challenge in the current work is to exploit the role of Heparin II binding 
domain and to concentrate growth factors of interest, such as those that are pro-EMT or 
anti-EMT at the signaling sites of the cell membrane. Initially, we investigated the 
localization of the fragments FNIII 12-14 delivered to cell membrane using FITC 
conjugated protein. We then investigated the effects of exogenous FNIII 12-14 on EMT 
using breast epithelial cells (MCF10A) in the presence or absence of TGF-β1 to 
determine whether FNIII 12-14 alters EMT signaling. Quantification of mRNA 
expression, for EMT markers such as Slug, Snail, Twist and ZEB1 were analyzed. 
Results showed that dosage increase of FNIII 12-14 appears to inhibit EMT 
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transcription factors. This study will develop a new understanding of disease and gene 
control using ECM proteins. The exploitation of ECM natural protein interactions could 
become a new method in turning on/off genes of interest. While we are currently 
investigating this as a mechanism of blocking EMT, it could also have implications in 
wound healing, fibrosis, and tissue engineering, where EMT is an important aspect of 
the physiologic progression. 
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Chapter 1: Introduction 
 Estimates from the American Cancer Society (ACS) for new diagnosed cases of 
and deaths from invasive breast cancer have been on the rise; hence, placing breast 
cancer as the second leading cause of death in women after lung cancer [4]. Both, the 
malignancy of the disease and lack of an absolute cure, in late stages, have 
encouraged our research team in investigating and helping to enrich the field with better 
assessments, diagnosis, and potentially effective treatments. Combined with our 
knowledge and passion of extracellular matrix (ECM) biology, we are able to further 
investigate cancer-causing processes, such as Epithelial-Mesenchymal Transition 
(EMT), and the ability of ECM proteins, such as Fibronectin (FN), in disease control. 
 ECM of an animal cell is commonly used as a guide to comprehend activities 
related to early invasion and tumor metastasis. One of the most commonly unregulated 
ECM proteins in cancer is FN. It has been widely studied for its significance in 
supporting embryogenesis [3], [4], differentiation [5], [6], and cell adhesion [9], [10]. It 
also plays an important role in cell stiffness and migration[11], and wound healing [12], 
[13]. It has been implicated that abnormally high expression of FN is an indication of 
early EMT; Followed by high rate of FN cleavage leads to metastasized cancer cells 
[14], [15]. Cancerous and fibrotic related health conditions usually initiate due to EMT 
processes known to uncontrollably up-regulate cell signaling and cause redundant pre-
inflammatory response. These processes have the ability to alter cell fate through back-
differentiation from a unipotent-epithelial to mutipotent-mesenchymal cell type. In adult 
tissue, these transitions lead cells to gain stem-cell like properties, such as migration 
and contractility, and become at risk of tumorigenesis and metastasize. 
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 Consequently, FN is considered a significant factor in the initiation of EMT 
processes. Due to its highly promiscuous growth factor (GF) binding domain, FNIII 12-
14, it is thought to enhance cellular signaling initiated from the ECM [16]–[18]. FNIII 12-
14 is also referred to Heparin II domain of FN, where it binds to cellular heparin. FN 
assembly into FN fibrils increases the number of localized FN, therefore FNIII 12-14, at 
the cell membrane. Previous work from our lab suggests that insoluble FN fibrils play a 
role in Transforming Growth Factor Beta 1 (TGF-β1)-induced EMT, due to their capacity 
in enhancing cell signaling through increased localization of the growth factor. This 
increase of co-localized growth factors cause an abnormal increase in cell signaling [3]. 
In other words, FN fibrils drive EMT by concentrating GFs, such as latent TGF-β 
complex, at the cell surface through FN repeats with notable affinity to growth factors.  
 Because this increase in cell signaling is due to the distinguished affinity to GFs, 
Heparin II domain is used in the study as exogenous fragments to potentially create a 
binding competition to GFs and alter the end outcomes of EMT. The challenge of our 
work is to prospectively reduce or block abnormal EMT processes through utilizing the 
role of FNIII 12-14 to seize growth factors from the ECM. We investigated the effects of 
exogenous FNIII 12-14 on EMT in the presence of the pro-EMT, TGF-β 1, growth factor 
using the human breast epithelial MCF10A cell line. Through immunofluorescence and 
FITC-conjugated FN fragments, we were able to verify the activity of the exogenous 
FNIII 12-14. Furthermore, we investigated other potential interactions between the ECM 
and FNIII 12-14. Gene expression studies were then developed to investigate the 
effects of the exogenous FNIII 12-14 on transcription factors known to elevate during 
EMT. We observed great changes in levels of Slug, Snail, Twist, and ZEB1.  
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Chapter 2: Background 
 The 2018 estimates from the American Cancer Society (ACS) show about 
268,670 new cases of breast cancer to be diagnosed, and 41,400 new deaths, of which 
most are females. The numbers estimated are approximately six percent higher than 
last year, keeping breast cancer in second place of leading cause of deaths in women 
after lung cancer [4], [19]. The increasing death toll every year is due to lack in absolute 
cure, which is a great motivation to our research team and other labs around the globe 
to investigate and help to enrich the field with better assessments, diagnosis, and 
potentially effective treatments. Combining our knowledge of molecular biology and 
extracellular matrix (ECM) biology, we are able to investigate the ability of fragments of 
extracellular proteins, such as Fibronectin (FN), and its interactions in disease control. 
 ECM is commonly used as a guide to comprehend activities related to wound 
healing, fibrosis, early invasion and tumor metastasis. Yet, cells use common signaling 
pathways for both wound healing and Epithelial-Mesenchymal Transition (EMT) [20]. 
These signaling pathways include biochemical, bioelectrical and/or biomechanical 
interactions between cellular components. The balance between all three is highly 
regulated in healthy conditions. On the other hand, and in some cases, small 
disruptions in key signal-regulators can propagate and cause nonreversible damage to 
cells. FN, for instance, has been widely studied for its significance in supporting 
embryogenesis [3], [4], differentiation [5], [6], cell adhesion [9], [10], cell stiffness and 
migration [11], and wound healing [12], [13]. It has been implicated that abnormally high 
expression of FN is an indication of early EMT; Followed by FN degradation, leading to 
metastasized cancer cells breaking through the matrix [14], [15].  
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 Epithelial to mesenchymal transition or EMT processes naturally occur in three 
forms: embryogenic and growth; fibrotic; and cancerous [21]–[24].EMT processes, 
depending on the micro-environment, can lead to one of the three cell types; secondary 
epithelial cells, fibroblast cells, or secondary cancer cells [25]. EMT is critical and highly 
regulated during embryogenesis and wound healing, which leads to organ development 
and tissue remodeling [22], [24], [26]. These processes have the ability to alter cell fate 
through back-differentiation from a unipotent-epithelial to mutipotent-mesenchymal cell 
type for growth and healing. On the other hand, misregulation of EMT can reprogram 
adult epithelial cells to become fibrotic or cancerous. Cancer and fibrotic-related health 
conditions have been suggested to initiate due to EMT processes known to up-regulate 
chemical and mechano-chemical cell signaling, causing redundant pre-inflammatory 
responses [27]–[29]. Nevertheless, in adult tissue, this transitioning leads cells to gain 
stem-cell like phenotypic properties, such as migration and increased rate in 
proliferation, becoming at risk for tumorigenesis and metastasis [30]. Metastasized cells 
have the ability to dissociate from original tissue, travel through the blood stream, and 
localize somewhere else in the body to form secondary tumors.  
 ECM composition differs from tissue to tissue, and can dictate a cell’s 
morphological properties. The ECM provides epithelial cells with strong E-cadherin-
based cell-cell junctions, an apicobasal polarity, and cortical actin cytoskeletal 
components. In mesenchymal-like cells, upregulated EMT individualizes cells, creates 
front-back polarity, causes spindle-like morphology of actin stress fibers, expresses N-
cadherin, FN and vimentin in addition to increasing motility and invasion [21]. EMT is 
also known to play a role in angiogenesis important for tumor survival [31]. Although 
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Transforming Growth Factor Beta 1 (TGF-β1) plays an important role in proliferation 
control of epithelial cells, it has been found to induce EMT [23], [32], [33], and promote 
tumor metastasis [34], [35]. Consequently, FN is considered a significant factor in the 
aiding of upregulation of EMT processes in epithelial cells [3], [36].  
 FN is a long extracellular protein which acquires a compact bulky shape in the 
soluble form. When bound to integrins on the cell surface, it becomes stretched along 
its two ends to form fibril-like orientated fibrils [37], [38]. FN becomes more abundant 
during tumor initiation processes, as well as embryogenesis and wound healing through 
EMT [39], [40]. When FN is bound to cells and stretched, domains of the protein, which 
were initially blocked from interactions due to the soluble form, become exposed and 
able to participate in signaling processes. The soluble bulky conformation of FN is 
usually due to amino acid interactions between itself. Such electrostatic interactions are 
usually seen between FNIII domains 2-4 and 12-14 [41].  
 Both soluble growth factors (GFs) and FNIII 2-4 compete to bind with the heparin 
domain III 12-14. Studies suggest that assembled FN fibrils play a role in GF delivery 
when TGF- β1 is bound in the activated form (LTBP-1 complex) to the heparin domain 
[42], [43]. FN type III 12, 13, and 14 repeats (FNIII 12-14) domains are a highly 
promiscuous GF binding region. This fragment is also a heparin binding domain (also 
called heparin domain II) [38]. FNIII 12-14 binds to many growth factors including TGF-
β1, and TGF-β1 appears to have a medium binding affinity to FNIII 12-14, in 
comparison to PDGF (low), FGF-2 and EGF (high) [44].  
 EMT signaling, which may play a role in the initiation of carcinoma cells, remains 
an active area of scientific research. It is suggested that initial EMT-inducing signals are 
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released by primary cancer cells, which are capable of altering neighboring cells 
genetically and epigenetically [25]. EMT signals of cancer cells are able to inhibit 
senescence causing the aggression in tumorigenesis [45]–[47]. Pro-EMT growth 
factors, such as EGF, PDGF, and TGF-β1, are linked to the activation of Snail, Slug, 
ZEB1, and Twist transcription factors [48]–[52]. The upregulated expression of any, or 
more than one, of those transcription factors is an indication of an oncogenesis activity.     
 Snail, Slug, ZEB1, and Twist are epithelial marker repressors and mesenchymal 
phenotypic promoters. For instance, when activated by downstream signaling pathways 
of TGF-β1, the transcription factors down-regulate cell-cell junctions by repressing E-
cadherin, as well as digest and remodel the ECM through over expression of FN and 
MMPs, giving the cell the ability to metastasize [53], [54]. Snail has also been found to 
promote cell invasiveness in mice [55], as well as oral and breast cancer in humans 
[56], [57]. Through gene expression analysis, researchers were able to identify Twist 
transcription factor as an EMT and metastasis inducer [58]. Therefore, using 
immunofluorescence staining techniques, markers such as E-cadherin, and peripheral 
actin filaments are here used to identify epithelial phenotypes, while FN, vimentin, and 
N-cadherin are used to identify cells with mesenchymal-like phenotype. 
 Since this increase in cellular signaling is due to the affinity and clustering of the 
pro-EMT growth factor on the cell membrane by FN Heparin II domain, introducing FNIII 
12-14 fragments to the cell media could potentially create a binding competition and 
alter the end outcomes of the pro-EMT GF TGF-β1. The hypothesis of our work is that 
EMT can be inhibited through the utilization of FNIII 12-14’s binding activity to 
competitively bind soluble growth factors around the cells. We investigated the effects of 
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exogenous FNIII 12-14 on EMT in the presence of TGF-β1 growth factor using the 
breast epithelial cell line MCF10A. Through immunofluorescence techniques along with 
conjugated protein, we were able to verify the localization of the exogenous protein, and 
investigate the mechanism of possible interactions with the ECM. Gene expression 
studies were then used to investigate the effects of the exogenous FNIII12-14 on mRNA 
expression of EMT transcription factors Slug, Snail, Twist and ZEB1. This study will 
develop a new understanding of how FN domains can be used to regulate GF pathways 
that bind to FN. While we are currently investigating this as a mechanism of blocking 
EMT, it could also have implications in wound healing, fibrosis, and tissue engineering, 
where FN fibril assembly is an important component of the physiological progression. 
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Chapter 3: Methods and Materials  
 
Cell culture and reagents 
 Human mammary epithelial cells (MCF10A) were purchased from the Oncology 
Bioresource Core Facility of the National Cancer Institute Physical Sciences, in 
conjunction with American Type Culture Collection (Manassas, VA). Cells were cultured 
in a humidified incubator at 37 °C and 5% CO2. Culture conditions for the cells were 
maintained using DMEM/F-12 HEPES obtained from Life Technologies, Carlsbad, CA, 
5% horse serum, 0.05% hydrocortisone, 0.01% cholera toxin, 0.1% insulin, 0.02% EGF 
and 1% antibiotics.  
 MCF10A cells were split and/or used for experiments just before cell monolayers 
reached full confluence (approximately 85-95%). This was done by incubating cells in 
0.05% Trypsin solution for 20 minutes and re-suspending cells with culture medium. 
Following a centrifugation step at 500 RPM for five minute at room temperature, 
supernatant solution was vacuumed, and fresh media was added to resuspend the 
pellet of cells. A ratio of 1:5 was used in the process. Active Transforming Growth 
Factor Beta 1 (TGF-β1) recombinant protein was obtained from Sigma Aldrich, St. 
Louis, MO. Antibody staining for immunofluorescence imaging was performed using the 
following primary antibodies; Mouse anti-Human E-cadherin (Abcam, Cambridge, 
United Kingdom), Rabbit anti-Human FN (Sigma Aldrich, St. Louis, MO). For F-actin 
imaging, cells were labeled using AlexaFluor555 Phalloidin (Life Technologies, 
Carlsbad, CA).  
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Expression and purification of FNIII 12-14  
 Fibronectin (FN) III 12-14 cDNA was received as a gift from Dr. Harold Erickson 
at Duke University. The DNA was previously inserted into ampicillin resistant E. coli 
bacteria vector (pET15b) containing a poly-histidine C-terminal tag and maltose binding 
protein (MBP), which aided in protein purification. Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) was used as a transcription promoter. For bacteria cell-lysing and protein-
degradation inhibition, reagents phenylmethane sulfonyl fluoride (PMSF) in isopropanol, 
ethylenediaminetetraacetic acid (EDTA), lysozyme, and 10% Triton-X 100 were used, in 
addition to -20⁰C overnight freeze.  PMSF, MgCl2, and DNAse were then added to the 
frozen culture and protein purification process was done using HisPurTM Cobalt Resin 
from Thermo Scientific.  
 During protein purification, Phosphate-buffered saline (PBS) was used for the 
washing steps, and 0.2 μM of imidazole in PBS was used for protein elution. For proper 
storage of the fragments, FNIII 12-14 protein, SephadexTM G-25 M kit from GE 
healthcare, Life Sciences, was used to perform buffer exchange using PBS as 
equilibrium, elution and storage buffer. FNIII 12-14 determination of A280 recombinant 
protein concentration was measured using NanoDrop 2000c spectrophotometer and 
software, Thermo Scientific.  
 Protein conjugation was performed using Fluorescein isothiocyanate isomer I 
(FITC) which was obtained from Sigma Life Sciences. FITC-FNIII 12-14 labeling was 
carried out using the following steps. FNIII 12-14 protein solution, of known 
concentration, was combined with freshly-made 1 M sodium bicarbonate buffer in 1:10 
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ratios, followed by mixing with newly dissolved 1mg/ml amine-reactive compound 
powder in DMSO. A total of 50 uL of the reactive dye was added per 1 mL of protein 
solution, in aliquots of 5 uL, with gentle vortexing in a dark room. The solution then was 
incubated at 4⁰C in the dark. Eight hours later, NH4Cl of 50 mM was added followed by 
a two hour incubation at 4⁰C.  
 Purification of the protein solution from unbound dye was done using 5% of 
Glycerol and 1% of BME followed by the use of SephadexTM G-25 M kit from GE 
healthcare. Concentration of conjugated protein, FITC-FNIII 12-14, was measured using 
NanoDrop 2000c spectrophotometer and software, Thermo Scientific, through UV-vis 
option set at 280 and 495 nm wavelengths. Excel software, was used for calculations to 
verify the rate of conjugation and protein concentration in moles, refer to Figure 1 for 
mathematical equations used in this step. 
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𝑹𝒂𝒕𝒊𝒐 𝒐𝒇 
𝑭𝑰𝑻𝑪
𝑷𝒓𝒐𝒕𝒆𝒊𝒏
 = ቀ
𝜺
𝟑𝟖𝟗ቁ
× ቎
𝑨𝟒𝟗𝟓
𝟏𝟗𝟓
𝑨𝟐𝟖𝟎 − (𝟎. 𝟑𝟓 ∗ 𝑨𝟒𝟗𝟓)
቏ 
𝑴𝒐𝒍𝒂𝒓𝒊𝒕𝒚 = [𝑨𝟐𝟖𝟎 − (𝑨𝟒𝟗𝟓 × 𝟎. 𝟑𝟓)] × ൬
𝟏𝟎𝟎𝟎𝟎𝟎𝟎
𝛆 ൰
 
 
ε:  Molar extinction coefficient of FNIII 12-14 
389:  The molecular weight of FITC 
195:  The absorption of bound FITC at 490 nm at pH 13.0 
0.35:  Correction factor due to the absorbance of FITC at 280 nm 
A280:  Absorbance of FNIII 12-14 at 280 
A495:  Absorbance of FNIII 12-14 at 495 
 
Figure 1: Equations Used for Protein Concentration Calculations  
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Immunofluorescence imaging  
 Immunofluorescence experiments were conducted using glass coverslips 
previously washed with ethanol and coated with 50 μg/ mL laminin (Sigma Aldrich, St. 
Louis MO) for two hours at 37 °C. MCF10A cells were seeded onto laminin-coated 12 or 
25-mm glass coverslips, in which cell count resulted in near confluent monolayers after 
overnight incubating (approximately 400,000 seeded cells per well). EGF and serum 
free medium was then used to growth factor-starve cells for two hours. Following the 
GF-free medium incubation, cells were treated with different dosages of FITC-FNIII 12-
14 (0, 1nM, 10nM, 100nM, 1μM, 5μM and 10μM) followed by treatment with/without 
TGF-β1 (10 ng/mL) and incubated for an additional 96 hours (See Table 1 for 
experiment setup). Cells’ plasma membrane was made permeable using 0.5% Triton in 
4% paraformaldehyde for two minutes, and incubated in 4% paraformaldehyde for 20 
minutes. Two PBS rinses were done, followed by 1% BSA incubation for five minutes 
and primary antibody incubation for 30 minutes at 37⁰C. Cells were then rinsed once 
with PBS for two minutes, and nonspecific-binding was eliminated by a five-minute 
incubation in 1% BSA followed by the appropriate secondary antibody application for 30 
min at 37C⁰. Nonspecific-binding blocking technique was performed for the last time 
following the use of fluoromount to attach coverslips to glass slides, which were then 
placed in the dark at room temperature for one hour to stabilize. Images were captured 
using Zeiss AxioObserver Z1 fluorescence microscope and ZEN2011 software. 
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 FNIII 12-14 (μM) 
 0 0.001 0.01 0.1 1 5 10 
(-)TGF-β1        
(+)TGF-β1        
 
Table 1: Immunofluorescence and Gene Expression Experiment Setup  
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Real time quantitative PCR analysis  
 Experiments were also conducted using glass coverslips previously washed with 
ethanol and coated with 50 μg/ mL laminin (Sigma Aldrich, St. Louis MO) for two hours 
at 37 °C. MCF10A cells were seeded on the laminin-coated 25-mm glass coverslips, in 
which cell counts (approximately 400,000) result in near confluent monolayers after 
overnight incubation period. EGF and serum free medium was then used to growth 
factor-starve cells for two hours. Following the GF-free incubation, cells were treated 
with different dosages of FNIII 12-14 (0, 1nM, 10nM, 100nM, 1μM, 5μM and 10μM) 
followed by treatment with/without TGF-β1 (10 ng/mL) and incubated for an additional 
96 hours, refer to table 1 above for experiment setup.  
 Extraction of total RNA was performed using RNeasy kit (Qiagen). Concentration 
of mRNA for each condition was then verified at or above the minimum concentration 
(100 ng/μL) via Nucleic acid built-in option on NanoDrop 2000c spectrophotometer and 
software, Thermo Scientific. The cDNA for mRNA sequences were then acquired using 
reverse transcriptase obtained from an iScript cDNA Synthesis Kit (Bio-Rad), and one 
PCR cycle using eppendorf Mastercycler pro equipment device.  
 The selective amplification of the cDNA was conducted by predesigned forward 
and reverse primers to genes of interest. The data for mRNA expressions were 
analyzed in response to primers for Snail, Slug, Twist, and ZEB1 (IDT). In addition, a 
housekeeper gene, 18s, specific primer set (IDT) was used for the normalization of 
data, refer to table 2 below for the complete primer sequence list. A 2X SYBR Green 
qPCR Master Mix, obtained from QUARTZY Bimake, was lastly added to qRT-PCR 
plates for the mRNA quantification assay which was performed using CFX Connect 
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Real-time System (Bio-Rad). Experiment data were collected and compared using gene 
study analysis using Bio-Rad CFX Manager and Microsoft Excel.  
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Marker Direction Nucleotide Sequence  
18s 
Forward 5'-GCA ATT ATT CCC CAT GAA CG-3' 
Reverse 5'-GGG ACT TAA TCA ACG CAA GC-3' 
Slug 
Forward 5'-CTC ACC TCG GGA GCA TAC AG-3' 
Reverse 5'-GAC TTA CAC GCC CCA AGG ATG-3' 
Snail 
Forward 5'-AAG ATG CAC ATC CGA AGC CA-3' 
Reverse 5'-CTC TTG GTG CTT GTG GAG CA-3' 
Twist 
Forward 5'-CTG CCC TCG GAC AAG CTG AG-3' 
Reverse 5'-CTA GTG GGA CGC GGA CAT GG-3' 
ZEB1 
Forward 5'-GTT CTG CCA ACA GTT GGT TT-3' 
Reverse 5'-GCT CAA GAC TGT AGT TGA AG-3' 
  
Table 2: Nucleotide Sequences for Forward and Reverse Primers Used in mRNA 
Quantification Analysis (Real-Time qPCR) 
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Chapter 4: Results  
 Immunofluorescence staining for each condition of MCF10A cells was completed 
using antibodies for E-cadherin (blue), F-actin (red), and FN (white). FNIII12-14 
treatments were added as FITC-tagged protein and therefore are presented in green. 
Based on multiple trials, presented below are representative images for the Epithelial-
Mesenchymal Transition (EMT) morphological markers (E-cadherin containing 
adherens junctions, actin organization, and FN assembly) for the negative TGF-β1 
conditions displayed below in Figure 2. The increase and the presence of FNIII 12-14 
alone appear to cause minimal morphological changes to E-cadherin junctions and actin 
(Figure 2). Furthermore, FN expression in the FN channel is seen in white inside cells 
and around the nuclei while assembly of FN can be seen as fibril-like aggregates on top 
or around cells. It appears that in response to the dose increase assembly and 
expression of FN stay consistently at low levels.  
 On the other hand, FNIII 12-14 effects on TGF- β1-induced EMT morphological 
markers in MCF10A cells, shown in Figure 3, appear to inhibit EMT, as cells appear 
similar to morphologies observed in the control conditions in Figure 2. Cells were also 
cultured for 96 hours, yet this time with 10 ng of TGF-β1 in the presence of FNIII 12-14 
treatment (ranging from 1nM to 10μM). In comparison with the positive control, molar 
concentration increase in FNIII 12-14, in the presence of 10ng/mL TGF-β1, appears to 
reduce morphological changes seen in the organization of E-cadherin junctions, yet 
morphological changes in actin appear to take place regardless of the amount present 
of the FN fragment. Interestingly, FN show visible reduction in protein expression and 
assembly in response to the dosage treatment of FNIII 12-14 (Figure 3).  
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 To further investigate the effects of FNIII 12-14 on TGF-β-induced EMT, 
transcription factor levels of Slug, Snail, Twist and ZEB1 from mRNA extraction 
following a 96 hour incubation were analyzed. The EMT related gene expression levels 
were evaluate from 14 conditions of two groups, (-) TGF-β1 and (+) TGF-β1. Each 
sample was run in triplicate during three trials. 
 Exogenous FNIII 12-14 with varying molar concentrations does not appear to 
influence TGF-β1–induced upregulation of Slug transcription factor in MCF10A cells 
(See Figure 4). Even though expression levels appear to fluctuate and reduce in 
response to treatments of 10nM, 100nM or 10μM of FNIII 12-14, statistical analysis 
show high percentage of random observations in the experiment (approximately 17%) in 
comparison to 0.01% of randomness in observed TGF-β1 effects. This resulted in 
insignificant affect interaction of the FN fragment to (+) TGF-β1 (See Figure 5). In the 
absence of exogenous TGF- β1, levels of Slug expression remain relatively low and 
constant as expected, regardless of the amount of FNIII 12-14 present. The inconsistent 
response of Slug levels seen in the analysis can be further seen in the ratio of change 
graph presented in Figure 4. 
 In contrast, FNIII12-14 treatments resulted in a consistent drop changes to Snail 
transcription factor levels in the presence of TGF-β1. This reduction in the transcription 
factor Snail was observed in the presence of all molar concentrations of the FN 
fragment along with (+) TGF-β1, except in the positive control where no FNIII 12-14 was 
added (See Figure 6). More specifically, at 10μM of FNIII 12-14, Snail levels appear to 
exhibit the maximum response of the inhibition interaction between the two factors. This 
can also be observed in the response change graph in Figure 6. Statistically, Snail 
26 | P a g e  
 
levels of expression changes due to the FN fragment in (+) TGF- β1 conditions appear 
to be rather nonrandom with a success chance of at least 96.9% (See Figure 7). Snail 
levels are confirmed unchanged in response to the presence of FNIII 12-14 alone.  
 Normalized mRNA expression levels for Twist in the presence of FNIII 12-14 and 
TGF-β1 show some degree of fluctuation. Yet, all conditions treated with both factors 
exhibit significant reductions in Twist expressed levels (See Figure 8). The 
concentration increase of FNIII 12-14, in the presence of TGF-β1 appears to maintain 
Twist expression at relatively close levels to those of (-) TGF- β1 (See Figure 8). The 
presence of FNIII 12-14 alone does not appear to promote Twist expression, especially. 
The change in Twist expression levels is highly significant with at least 97% success. 
FNIII 12-14 appear to be somehow interacting with TGF-β1 preventing changes to Twist 
expression levels, significantly seen in Figure 9.  
 Averaged and normalized transcription factor ZEB1 expression levels were 
obtained in relationship to the presence of 1nM to 10μM of FNIII 12-14, with and without 
TGF- β1. As seen in Figure 10, the concentration increase of FNIII 12-14 appears to 
cause a reduction in (+) TGF-β1-induced ZEB1 expression levels. No increase in ZEB1 
expression levels in response to presence of exogenous FNIII12-14 alone is observed. 
Levels of ZEB1 expression appear to stay relatively low in response to the presence of 
both factors, which was statistically verified to be at 99.9% significance (Figure 11). 
 Observations from overlapped line charts in Figure 12 for the transcription factors 
suggest that ratio of change takes almost the same pattern with dose increase of FNIII 
12-14. It is also statistically evident that significant transcription factor reduction 
changes take place in Snail, Twist and ZEB1 in the presence of TGF-β1. Although each 
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molar concentration higher than 0nM of FNIII 12-14 result in significant inhibition of 
EMT-induced Snail, Twist and ZEB1, most significant drop change in all three 
transcription factors is observed at treatments of 10μM (Se Figure 12). In other words, 
exogenous treatments of FNIII 12-14 between 1nM and 10μM display signaling 
regulation opposed to what is normally seen due to the solely presence of recombinant 
TGF-β1 in Slug, Twist and ZEB1, yet does not have observed significant effects on Slug 
nor exhibits prime influence on any of the transcription factors in the absence of TGFβ1 
(See Figure 12).  
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Figure 5: Statistical analysis for FNIII 12-14 effects on the EMT marker Slug expression 
levels. Cells were incubated for 96 hours before mRNA was extracted for gene 
expression analysis. Changes of Slug expression in response to 1nM to 10μM of 
exogenous FNIII 12-14 were averaged between three experiment trials and normalized 
to the (-) control. Levels of mRNA expression were determined by means of RT-qPCR. 
N = 9 for each condition of the three trials. Grouped statistical analysis using two-way 
ANOVA and Bonferroni's multiple comparisons tests were performed using GraphPab 
Prism 7.04 software. P-value>0.09. 
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Figure 7: Statistical analysis for FNIII 12-14 effects on the EMT marker Snail expression 
levels. Cells were incubated for 96 hours before mRNA was extracted for gene 
expression analysis. Changes of Snail expression in response to 1nM to 10μM of 
exogenous FNIII 12-14 were averaged between three experiment trials and normalized 
to the (-) control. Levels of mRNA were determined by means of RT-qPCR. N = 9 for 
each condition of the three trials. Grouped statistical analysis using two-way ANOVA 
and Bonferroni's multiple comparisons tests were performed using GraphPab Prism 
7.04 software. (*) P-value<0.03. 
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Figure 8: Effects of FNIII 12-14 on 
incubated for 96 hours before mRNA was extracted for gene ex
conditions were normalized to the (
using the ratio of (+)/ (-) TGF-
of FN fragment used. Levels of mRNA were determined by 
for each condition of the three
  
the EMT marker Twist expression levels
pression analysis. 
-) control. Ratio of change analysis was completed 
β1 for Twist expressed levels for each molar concentration 
means of RT
 trials. 
 
. Cells were 
All 
-qPCR. N = 9 
33 | P a g e  
 
 
 
 
 
Co
ntr
ol
1n
M
10
nM
10
0n
M
1u
M
5u
M
10
uM
No
rm
al
iz
ed
 E
xp
re
ss
io
n
 
 
Figure 9: Statistical analysis for the effects of FNIII 12-14 on EMT marker Twist mRNA 
expression. Cells were incubated for 96 hours before mRNA was extracted for gene 
expression analysis. Changes in Twist levels in response to 1nM to 10μM of exogenous 
FNIII 12-14 were averaged between three experiment trials and normalized to the (-) 
control. Levels of mRNA were determined by means of RT-qPCR. N = 9 for each 
condition of the three trials. Grouped statistical analysis using two-way ANOVA and 
Bonferroni's multiple comparisons tests were performed using GraphPab Prism 7.04 
software. (*) P-value<0.02. 
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Figure 10: Effects of FNIII 12
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Figure 11: Statistical analysis for the effects of FNIII 12-14 on EMT marker ZEB1 mRNA 
expression. Cells were incubated for 96 hours before mRNA was extracted for gene 
expression analysis. Changes in ZEB1 levels in response to 1nM to 10μM of exogenous 
FNIII 12-14 were averaged between three experiment trials and normalized to the (-) 
control. Levels of mRNA were determined by means of RT-qPCR. N = 9 for each 
condition of the three trials. Grouped statistical analysis using two-way ANOVA and 
Bonferroni's multiple comparisons tests were performed using GraphPab Prism 7.04 
software. (*) P-value<0.0001. 
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Figure 12: Exogenous FNIII 12
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Chapter 5: Discussion  
 FNIII 12-14 is recognized as a promiscuous growth factor (GF) binding protein, 
aids in Transforming Growth Factor Beta 1 (TGF-β1) localization which promotes TGF-
β1-induced upregulation of Epithelial-Mesenchymal Transition (EMT) during Fibronectin 
(FN) polymerization. Previous work from our lab has shown that self-assembly of FN 
into insoluble fibrils is crucial for EMT [3]. Additionally, our lab previously suggested that 
upregulation of FN fibril formation further drive EMT through contractility due to the 
increase amount of the GF latent TGF-β complex at the cell membrane [3].  
 Immunofluorescence images for TGF-β1-induced cell markers suggest that 
exogenous FNIII 12-14 is able to reduce EMT morphological transformation in MCF10A 
cells. Transdifferentiation markers for EMT remain mostly epithelial-like, even in the 
presence of exogenous 10ng/mL of TGF-β1. Following 96 hours incubation of MCF10A 
cells with FNIII12-14 and TGF-β1, E-cadherin cell junctions appear to somehow 
maintain its morphological organization opposing the effects of EMT induction. Actin 
spindle-like morphology did not show significant changes in response to the FN 
fragment-TGF-β1 interactions. FN expression and assembly appeared to be both 
reduced, yet immunoprecipitation and protein quantification techniques could confirm 
these observations in future studies.  This supports results from other studies 
suggesting that FN assembly can be inhibited by exogenous FNIII 12-14 or other 
fragments containing heparin domain [59]. Moreover, FN fragments appear to have 
relatively higher cell binding affinity when recombinant TGF-β1 is added. This is likely 
due to initial TGF-β1-induced cell contractility [60]; which facilitates essential ligand 
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binding protein interactions at the plasma membrane before leaving the receptor to be 
captured by the soluble FN fragment [1], [61].  
 Upregulation in expression levels of transcription factor Slug, Snail, Twist and 
ZEB1 are recognized as EMT-induced cellular signaling [62]–[68]. Upon multiple trials of 
mRNA quantification, we demonstrated that exogenous FNIII 12-14 at concentrations 
between 1nM and 10μM produces reduction responses in Snail, ZEB1, and Twist 
mainly in the presence of TGF-β1. Yet Slug expression levels fail to provide statistical 
evidence for which response to FNIII 12-14 could be happening. Additional tested 
considered to be performed to reveal more evidence for whether Slug signaling 
participates due to the interaction activity of exogenous FNIII 12-14 and TGF-β1. 
 Although it is insignificant in Slug, transcription factors Snail, Twist, and ZEB1 
expression levels appear to have maximum decline roughly at 10μM of the molar 
concentration of FN fragment. Snail, Twist and ZEB1 levels are somewhat reduced and 
stay constant between 1nM and 5μM. It is likely that molecular diffusion and binding 
affinity play a role in the fate of TGF-β1-FNIII 12-14 complex across the multiple 
conditions. Therefore, our theory is that exogenously added low amounts of FN 
fragment bind most soluble TFG-β1 factors through heparin and electrostatic 
interactions [18]; reducing GFs available for cell signaling, and therefore EMT effects. At 
higher concentrations of FNIII 12-14 (approximately 10μM), FN assembly is completely 
inhibited due to the presence of high amounts of heparin domain fragments [59]; 
therefore further inhibiting stable binding of TGF-β1 to cell membrane. Interestingly, 
studies have shown a degree of success the use of FN fragments for protein delivery 
[16], [44].  
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 FNIII 12-14-TGF-β1 complex could also be inhibiting back differentiation of 
epithelial to mesenchymal cell type activity, yet the FN fragment might be partially 
ineffective towards a number of genes activated by TGF-β1, such as those that are 
transcripted by Slug and/or transforming actin organization. This could explain why 
changes in Snail and actin are rather non-responsive to the presence of FNIII 12-14. It 
is also essential to take into consideration that FNIII 12-14-TGF-β1 binding affinity is 
intermediate in contrast to other GFs; and that FNIII 12-14 is capable of maintaining the 
GF bounds for multiple days [44]. 
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Chapter 6: Conclusion and Future Directions 
 
 In the study, we hypothesis that TGF-β1-induced misregulation of cellular 
morphology and transcription factors (Snail, Twist and ZEB1) can be inhibited by 
exogenous FNIII 12-14 in amounts of 1nM to 1μM. This will significantly hinder EMT 
markers: E-cadherin degradation and FN assembly as seen in Figure 2 and 3. 
Nevertheless, Normalized changes in Slug, Twist and ZEB1 transcription factor 
expression levels between all conditions appear to further support our conclusion in that 
the overall upregulation effect of TGF-β1 on EMT transcription factors can be 
significantly reduced as much as 60% using 1nM of exogenous FNIII 12-14. Therefore, 
we characterize FNIII 12-14 as an inhibitor for Snail, ZEB1 and Twist signaling due to its 
competitive binding that leads to minimizing the reach of growth factors (GFs) to the cell 
membrane. This characterization of the FNIII 12-14 is verified in our study by blocking 
TGF-β1 upregulatory activity when 1nM - 10μM exogenous FN fragments is used. The 
study does not provide significant evidence for TGF- β1 delivery by FNIII 12-14. 
Additionally, our study confirms that exogenous FNIII 12-14 alone does not induce 
transcriptional or morphological EMT markers in human epithelial MCF10A cells. 
 Due to response behavior seen in Snail, Twist and ZEB1 in the presence of FNII 
12-14 and TGF-β1, we plan to perform additional tests to reveal whether other signaling 
pathways might be altered by the FN fragment FNIII 12-14. Using quantitative analysis, 
we will further verify the effects of the FN fragments on FN expression levels. 
Investigations of anti-EMT GF signaling activities hold potential discoveries in 
mesenchymal-epithelial transition (MET) and the future of cancer medicine. Therefore, 
we have considered studying the effects of treating pre-EMT transformed human 
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epithelial cells with exogenous FNIII 12-14 and anti-EMT GFs such as CTGF [69]; or 
BMP-2 [70] by means to enhance the processes of MET. We encourage the field to 
further investigate the molecular interactions between FNIII 12-14, GFs, and cell 
membrane proteins, competitive affinity binding and release, other possible cellular 
signaling cascades altered by the FN fragment, and variety of proteins for the ECM 
delivery. Studying binding affinities between FNIII 12-14 and membrane proteins, such 
as integrins, could provide us with more insights on FNIII 12-14 fragments favorable 
interactions in vitro. 
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